BQ.1.1、XBB.1 和 XBB.1.5 对癌症患者二价 mRNA COVID-19 加强针的中和作用。
BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer.
机构信息
Department of Oncology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Academy of Geriatric Oncology, Odense University Hospital, Odense, Denmark.
Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Clinical Microbiology, Odense University Hospital, Odense, Denmark.
出版信息
Cancer Cell. 2023 Apr 10;41(4):649-650. doi: 10.1016/j.ccell.2023.02.003. Epub 2023 Feb 9.
Abstract
Ehmsen et al. evaluate the neutralizing capacity to current SARS-CoV-2 variants in patients with cancer before and after receiving the BNT162b2 bivalent mRNA vaccine booster. Bivalent vaccine provides some protection against BQ.1.1 but fails to protect against XBB.1 and XBB.1.5 in patients with cancer.
摘要
埃姆森等人评估了癌症患者在接种 BNT162b2 二价 mRNA 疫苗加强针前后对当前 SARS-CoV-2 变体的中和能力。二价疫苗对 BQ.1.1 提供了一定程度的保护，但不能预防癌症患者感染 XBB.1 和 XBB.1.5。
相似文献
1
BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer.BQ.1.1、XBB.1 和 XBB.1.5 对癌症患者二价 mRNA COVID-19 加强针的中和作用。
Cancer Cell. 2023 Apr 10;41(4):649-650. doi: 10.1016/j.ccell.2023.02.003. Epub 2023 Feb 9.
2
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.早期估计，二价 mRNA 加强针在预防免疫功能正常成年人因奥密克戎 BA.5-和 XBB/XBB.1.5 相关亚谱系导致的有症状 SARS-CoV-2 感染方面的有效性-增加社区获得检测计划，美国，2022 年 12 月至 2023 年 1 月。
MMWR Morb Mortal Wkly Rep. 2023 Feb 3;72(5):119-124. doi: 10.15585/mmwr.mm7205e1.
3
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.原始mRNA疫苗或BA.5二价加强针 对SARS-CoV-2奥密克戎BA.2.75.2、BQ.1.1和XBB.1的中和作用较低。
Nat Med. 2023 Feb;29(2):344-347. doi: 10.1038/s41591-022-02162-x. Epub 2022 Dec 6.
4
Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations.二价新冠疫苗接种者对BQ.1.1、BN.1和XBB.1的中和活性：按既往感染类型和疫苗配方进行比较
Vaccines (Basel). 2023 Aug 4;11(8):1320. doi: 10.3390/vaccines11081320.
5
Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster.四价 COVID-19 疫苗加强针增强对 SARS-CoV-2 变异株 BA.2.86 和 XBB 亚谱系的中和作用。
Cell Host Microbe. 2024 Jan 10;32(1):25-34.e5. doi: 10.1016/j.chom.2023.11.012. Epub 2023 Nov 28.
6
Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID-19 booster dose in persons with HIV.在 HIV 感染者中，二价 mRNA COVID-19 加强针接种后对 XBB 亚谱系的中和反应持久性差。
J Med Virol. 2024 Apr;96(4):e29598. doi: 10.1002/jmv.29598.
7
Humoral Responses Elicited after a Fifth Dose of SARS-CoV-2 mRNA Bivalent Vaccine.第五剂 SARS-CoV-2 mRNA 双价疫苗后诱导的体液反应。
Viruses. 2023 Sep 15;15(9):1926. doi: 10.3390/v15091926.
8
Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.辉瑞-BioNTech 新冠疫苗接种 6 个月后针对 SARS-CoV-2 关注变异株的抗体反应
Microbiol Spectr. 2022 Apr 27;10(2):e0225221. doi: 10.1128/spectrum.02252-21. Epub 2022 Mar 9.
9
Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.2022 年 8 月 31 日至 10 月 23 日，12 岁及以上人群中双价 COVID-19 mRNA 疫苗加强针的安全性监测-美国。
MMWR Morb Mortal Wkly Rep. 2022 Nov 4;71(44):1401-1406. doi: 10.15585/mmwr.mm7144a3.
10
In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant.体外中和活性的 BNT162b2 mRNA 诱导的抗体对完整的 B.1.351 SARS-CoV-2 变体。
Transbound Emerg Dis. 2022 Sep;69(5):2649-2655. doi: 10.1111/tbed.14417. Epub 2022 Jan 3.
引用本文的文献
1
Transcriptomic profiling of burn patients reveals key lactylation-related genes and their molecular mechanisms.烧伤患者的转录组分析揭示关键的乳酸化相关基因及其分子机制。
Front Med (Lausanne). 2025 Jun 27;12:1554791. doi: 10.3389/fmed.2025.1554791. eCollection 2025.
2
Comparison of a SARS-CoV-2 mRNA booster immunization containing additional antigens to a spike-based mRNA vaccine against Omicron BA.5 infection in hACE2 mice.在hACE2小鼠中，将含额外抗原的SARS-CoV-2 mRNA加强免疫与基于刺突蛋白的mRNA疫苗针对奥密克戎BA.5感染进行比较。
PLoS One. 2024 Dec 3;19(12):e0314061. doi: 10.1371/journal.pone.0314061. eCollection 2024.
3
New variants of COVID-19 (XBB.1.5 and XBB.1.16, the "Arcturus"): A review of highly questioned concerns, a brief comparison between different peaks in the COVID-19 pandemic, with a focused systematic review on expert recommendations for prevention, vaccination, and treatment measures in the general population and at-risk groups.新型冠状病毒变异株（XBB.1.5 和 XBB.1.16，即“Arcturus”）：备受质疑的问题综述，对 COVID-19 大流行不同高峰期的简要比较，以及对普通人群和高危人群预防、接种和治疗措施的专家建议进行的重点系统评价。
Immun Inflamm Dis. 2024 Jun;12(6):e1323. doi: 10.1002/iid3.1323.
4
An mRNA vaccine encoding the SARS-CoV-2 receptor-binding domain protects mice from various Omicron variants.一种编码严重急性呼吸综合征冠状病毒2（SARS-CoV-2）受体结合域的信使核糖核酸（mRNA）疫苗可保护小鼠免受多种奥密克戎变体的侵害。
NPJ Vaccines. 2024 Jan 2;9(1):4. doi: 10.1038/s41541-023-00800-0.
5
Neutralizing response against SARS-CoV-2 Omicron BA.5 and XBB.1.5 in hemodialysis patients.血液透析患者对新冠病毒奥密克戎BA.5和XBB.1.5的中和反应。
Clin Kidney J. 2023 Sep 12;16(12):2757-2759. doi: 10.1093/ckj/sfad230. eCollection 2023 Dec.
6
Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination.尽管基于原型的疫苗接种反复进行，但在 BA.5/ BF.7 突破性感染后，针对奥密克戎亚变种的中和作用随着病毒进化和老化而减弱。
Emerg Microbes Infect. 2023 Dec;12(2):2249121. doi: 10.1080/22221751.2023.2249121. Epub 2023 Sep 5.
7
Serum Neutralization of Omicron XBB.1.5 in Kidney Transplant Recipients After Bivalent mRNA Booster Vaccination.二价mRNA加强疫苗接种后肾移植受者血清对奥密克戎XBB.1.5的中和作用
Kidney Int Rep. 2023 May 26;8(8):1665-8. doi: 10.1016/j.ekir.2023.05.020.
8
Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients.癌症患者 COVID-19 疫苗接种后针对 SARS-CoV-2 奥密克戎 BA.1 及其亚变体 BA.4/5 和 BQ.1.1 的体液反应和中和抗体的纵向数据。
J Cancer Res Clin Oncol. 2023 Sep;149(12):10633-10644. doi: 10.1007/s00432-023-04961-2. Epub 2023 Jun 10.
9
Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study.加强针接种后的抗体反应对晚期癌症患者 SARS-CoV-2 突破感染和疾病结局的影响：Vax-on-Third 研究的前瞻性分析。
Curr Oncol. 2023 May 17;30(5):5103-5115. doi: 10.3390/curroncol30050386.
10
A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included Omicron variants of SARS-CoV-2.一种重组刺突-XBB.1.5蛋白疫苗可诱导针对包括XBB.1.5在内的SARS-CoV-2奥密克戎变体的广谱免疫反应。
MedComm (2020). 2023 Apr 26;4(3):e263. doi: 10.1002/mco2.263. eCollection 2023 Jun.
Zotero 插件